Arsenic and Old Lace: Novel Approaches in Elderly Patients With Acute Myeloid Leukemia

Osler, 1886, On the use of arsenic in certain forms of anaemia, The Therapeutic Gazette 3rd Series, II, 741 Haller, 1975, Therapeutic mule: The use of arsenic in the nineteenth century materia medica, Pharm Hist, 17, 87 Miller, 2002, Mechanisms of action of arsenic trioxide, Cancer Res, 62, 3893 Rojewski, 2004, Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: From bench to bedside, Leuk Lymphoma, 45, 2387, 10.1080/10428190412331272686 Rojewski, 2002, Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: Induction of apoptosis and inhibition of proliferation, Br J Haematol, 116, 555, 10.1046/j.0007-1048.2001.03298.x Roboz, 2000, Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis, Blood, 96, 1525, 10.1182/blood.V96.4.1525 Burnett, 2007, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment, Cancer, 109, 1114, 10.1002/cncr.22496 Parmar, 2004, Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old, Leuk Res, 28, 909, 10.1016/j.leukres.2003.12.012 Douer, 2005, Durable molecular remission in two acute promyelocytic leukemia (APL) patients treated with arsenic trioxide at first molecular relapse, Blood, 106, 525a, 10.1182/blood.V106.11.1847.1847